Evidence map›Paper›PMID 40213264›Full record

ArticleHealth science reports2025

Polypharmacy and Potentially Inappropriate Medication in Iranian People With Metabolic Syndrome: Epidemiological Aspects and Related Factors, a Multi-Level Cross-Sectional National Study.

Mojdeh Daneshmand, Hamidreza Jamshidi, Mohammad-Reza Malekpour, Erfan Ghasemi, Sahar Saeedi Moghaddam, Seyede Salehe Mortazavi, Mohsen Shati, Mohammad Hadi Farjoo, Farshad Farzadfar

Abstract read
In one paragraph

Article in Health science reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Mojdeh DaneshmandDepartment of Pharmacology, School of Medicine Shahid Beheshti University of Medical Sciences Tehran Iran.ORCID 0000-0002-0659-1003
Hamidreza JamshidiDepartment of Pharmacology, School of Medicine Shahid Beheshti University of Medical Sciences Tehran Iran.ORCID 0000-0001-6887-1409
Mohammad-Reza MalekpourNon-Communicable Diseases Research Center, Endocrinology and Metabolism Population Sciences Institute Tehran University of Medical Sciences Tehran Iran.ORCID 0000-0002-8648-5402
Erfan GhasemiNon-Communicable Diseases Research Center Tehran University of Medical Sciences Tehran Iran.ORCID 0000-0003-1005-3272
Sahar Saeedi MoghaddamNon-Communicable Diseases Research Center Tehran University of Medical Sciences Tehran Iran.
Seyede Salehe MortazaviGeriatric Mental Health Research Canter School of Behavioural Sciences and Mental Health Iran University of Medical Sciences Tehran Iran.ORCID 0000-0003-4565-9688
Mohsen ShatiDepartment of Epidemiology, Psychosocial Health Research Institute Mental Health Research Centre Tehran Iran.ORCID 0000-0001-7738-2180
Mohammad Hadi FarjooDepartment of Pharmacology, School of Medicine Shahid Beheshti University of Medical Sciences Tehran Iran.ORCID 0000-0001-7765-6970
Farshad FarzadfarNon-Communicable Diseases Research Center Tehran University of Medical Sciences Tehran Iran.ORCID 0000-0001-8288-4046

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background and Aims: Polypharmacy, characterized by the concurrent use of five or more medications in a prescription, potentially resulting in adverse outcomes, is frequently observed among individuals with metabolic syndrome, which encompasses a collection of conditions that co-occur, heightening the likelihood of heart disease, stroke, and type 2 diabetes. This study seeks to ascertain the prevalence of polypharmacy and the use of potentially inappropriate medications (PIMs) among Iranian patients with metabolic syndrome, while also evaluating the contributing individual and sociodemographic factors. Methods: This was a population-based, cross-sectional national study. Two databases were used: (a) Iranians Health Insurance Service database and (b) Iran's STEPS 2016 survey. Patients with metabolic syndrome conjoint in both databases were selected. Among these patients, polypharmacy and PIM were evaluated, and their association with individual and sociodemographic factors was assessed. Univariate and multivariate logistic regression were used to analyze the associations. All statistical analyses were done using SPSS 22 and Python 3. Results: Out of 2075 metabolic syndrome patients, 10.3% had polypharmacy. Polypharmacy significantly increased by age (OR: 4.334, adjusted for > 80-year-olds vs. 25-39-year-olds [CI: 1.664-11.283], Conclusions: Since the area of residency affects polypharmacy and PIM more significantly than wealth status and education level, it is important to implement preventive measures in urban areas.

Indexed as

metabolic syndromepolypharmacypotentially inappropriate medicationsociodemographic

Identifiers

PMID40213264
PMCPMC11982520

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.